You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 9,765,028

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,765,028

Title:	Crystalline freebase forms of a biphenyl compound
Abstract:	The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piper- idin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Inventor(s):	Woollam; Grahame (Basel, CH)
Assignee:	Theravance Biopharma R&D IP, LLC (South San Francisco, CA)
Application Number:	15/206,877
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,765,028
Patent Claims:	1. Crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}-ethyl)pipe- ridin-4-yl ester characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2.theta. values of 6.6.+-.0.1, 13.1.+-.0.1, 18.6.+-.0.1, 19.7.+-.0.1, and 20.2.+-.0.1; and further characterized by having five or more additional diffraction peaks at 2.theta. values selected from 8.8.+-.0.1, 10.1.+-.0.1, 11.4.+-.0.1, 11.6.+-.0.1, 14.8.+-.0.1, 15.2.+-.0.1, 16.1.+-.0.1, 16.4.+-.0.1, 16.9.+-.0.1, 17.5.+-.0.1, 18.2.+-.0.1, 19.3.+-.0.1, 19.9.+-.0.1, 20.8.+-.0.1, 21.1.+-.0.1, 21.7.+-.0.1, and 22.3.+-.0.1. 2. Crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}-ethyl)piper- idin-4-yl ester characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2.theta.values selected from 6.6.+-.0.1, 11.4.+-.0.1, 13.1.+-.0.1, 16.1.+-.0.1, 17.5.+-.0.1, 18.2.+-.0.1, 18.6.+-.0.1, 19.3.+-.0.1, 19.7.+-.0.1, 19.9.+-.0.1, 20.2.+-.0.1, 20.8.+-.0.1, 21.1.+-.0.1, 21.7.+-.0.1, and 22.3.+-.0.1. 3. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier; and (b) crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]-methylamino}ethyl)pipe- ridin-4-yl ester characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2.theta. values of 6.6.+-.0.1, 13.1.+-.0.1, 18.6.+-.0.1, 19.7.+-.0.1, and 20.2.+-.0.1; and further characterized by having five or more additional diffraction peaks at 2.theta. values selected from 8.8.+-.0.1, 10.1.+-.0.1, 11.4.+-.0.1, 11.6.+-.0.1, 14.8.+-.0.1, 15.2.+-.0.1, 16.1.+-.0.1, 16.4.+-.0.1, 16.9.+-.0.1, 17.5.+-.0.1, 18.2.+-.0.1, 19.3.+-.0.1, 19.9.+-.0.1, 20.8.+-.0.1, 21.1.+-.0.1, 21.7.+-.0.1, and 22.3.+-.0.1. 4. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier; and (b) crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]-methylamino}ethyl)pipe- ridin-4-yl ester characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2.theta. values selected from 6.6.+-.0.1, 11.4.+-.0.1, 13.1.+-.0.1, 16.1.+-.0.1, 17.5.+-.0.1, 18.2.+-.0.1, 18.6.+-.0.1, 19.3.+-.0.1, 19.7.+-.0.1, 19.9.+-.0.1, 20.2.+-.0.1, 20.8.+-.0.1, 21.1.+-.0.1, 21.7.+-.0.1, and 22.3.+-.0.1. 5. Crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piper- idin-4-yl ester characterized by a powder x-ray diffraction pattern having peak positions in accordance with the peak positions shown in FIG. 1. 6. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier; and (b) crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyfl]methylamino}ethyl)pipe- ridin-4-yl ester characterized by a powder x-ray diffraction pattern having peak positions in accordance with the peak positions shown in FIG. 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.